search
Back to results

Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus

Primary Purpose

Type 1 Diabetes Mellitus

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Islet Transplantation and Bone Marrow
Sponsored by
University of Miami
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 1 Diabetes Mellitus focused on measuring Islet Transplantation

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients between 18 and 65 years of age Patients with type 1 diabetes mellitus for more than 5 years duration One or more of the following: Hypoglycemia unawareness - judged by history of blood sugars <54 on glucometer without symptoms and/or hypoglycemic episodes requiring assistance from either family, glucagon administration or emergency services Poor diabetes control (HbA1c>8% or >2 visits/yr to hospital for treatment of ketoacidosis) despite intensive insulin therapy Progressive complications of type 1 diabetes mellitus Body Mass Index (BMI) ≤26 Exclusion Criteria: Untreated proliferative diabetic retinopathy; HbA1C > 12%; Insulin requirement > 1.0u/kg/d Stimulated or basal C-peptide > 0.3 ng/ml Creatinine clearance < 60 and/or serum creatinine consistently > 1.5mg/dl; Macroalbuminuria > 300mg albumin in 24 hours Presence of panel reactive antibodies > 20%; Previous/concurrent organ transplantation (except failed islet cell transplantation); Any medical condition requiring chronic use of steroids; Malignancy or previous malignancy (except non-melanomatous skin cancer); X-ray evidence of pulmonary infection; Active infections; Positive tuberculin test (unless proof of adequate treatment for latent tuberculosis can be provided) Active peptic ulcer disease, Gall stones and/or portal hypertension and/or hemangioma on liver ultrasound; Serological evidence of HIV, HBV (HBsAg+ and/or HBcAb+ and/or HBsAb+ without evidence of vaccination), HTLV-1 or HCV; Negative serology for Epstein Barr virus (EBV) or evidence of acute infection (IgM>IgG); Abnormal liver function test; Anemia (hemoglobin <12.0 g/dl); Hyperlipidemia (fasting total cholesterol >240mg/dl and/or fasting triglycerides >200mg/dl and/or fasting LDL cholesterol>140mg/dl); Body Mass Index above 26 and/or weight >80kg; Prostate specific antigen (PSA) > 4 ng/ml; Unstable cardiovascular status (including positive stress echocardiography if >age 35); Active alcohol or substance abuse; Sexually active females who are not: a) post-menopausal, b) surgically sterile, or c) not using an acceptable method of contraception (oral contraceptives, Norplant, Depo-Provera, and barrier devices are acceptable; condoms used alone are not acceptable); Positive pregnancy test or intent for future pregnancy, or male subject's intent to procreate. Any condition or any circumstances that makes it unsafe to undergo an islet cell transplant. History of previous transplant or previous bone marrow infusion. Persistent leucopenia (white blood cell count <3,000/mm3

Sites / Locations

  • Diabetes Research Institute

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Islet Transplantation and Bone Marrow

Arm Description

Administration of islets and infusion of CD34 enriched Bone Marrow cells in subjects with type 1 diabetes, impaired awareness of hypoglycemia and severe hypoglycemia.

Outcomes

Primary Outcome Measures

The Achievement of Persistent Islet Function Following Cessation of Immunosuppression.
Immunosuppression was never discontinued. Patients elected to move to other trials to receive additional islet infusions. Since immunosuppression was never discontinued we were not able to evaluate the primary endpoint.
A Reduction or Absence of Rejection Episodes
Number of rejection episodes after transplantation. Immunosuppression was never discontinued. Patients elected to move to other trials to receive additional islet infusions. Since immunosuppression was never discontinued we were not able to evaluate the primary endpoint.

Secondary Outcome Measures

Number of Subjects With Basal C-peptide Greater Than 0.5 ng/ml
Number of subjects with basal C-peptide greater than 0.5 ng/ml prior to weaning of immunosuppression;
Number of Subjects With Reduction of Severe Hypoglycemia and Improvement in Hypoglycemia Awareness
Number of subjects with reduction of episodes of severe hypoglycemia and the presence of awareness of hypoglycemia

Full Information

First Posted
April 14, 2006
Last Updated
March 29, 2017
Sponsor
University of Miami
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Diabetes Research Institute Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT00315614
Brief Title
Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus
Official Title
Islet Cell Transplantation Alone and CD34+ Enriched Donor Bone Marrow Cell Infusion in Patients With Type 1 Diabetes Mellitus; Steroid Free Regimen
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Terminated
Why Stopped
We did not achieve a tolerogenic profile. Subjects withdrew from protocol and enrolled in other islet transplant trials.
Study Start Date
December 2000 (undefined)
Primary Completion Date
December 2010 (Actual)
Study Completion Date
December 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Miami
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Diabetes Research Institute Foundation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
SPECIFIC AIMS: To reverse hyperglycemia and insulin dependency in patients with Type 1 diabetes mellitus by islet cell transplantation. To induce a state of donor specific tolerance and eliminate the need for continuous immunosuppressive therapy by simultaneous transplantation of donor bone marrow cells with islets and utilization of the monoclonal antibody Campath-1H for induction of Immunosuppression. To assess long-term function of successful islet cell transplants in patients with Type 1 diabetes mellitus. To determine whether the natural history of the microvascular, macrovascular and neuropathic complications are altered following successful transplantation of islet
Detailed Description
In our current protocol (IRB #2000/0024) the immunosuppressive regimen, comprised of induction with daclizumab and maintenance therapy with sirolimus and tacrolimus, has been combined with the infusion of CD34+ enriched donor bone marrow stem cells in an attempt to create a chimeric state and hence induce donor tolerance. This strategy was tested by evaluating graft survival following the removal of all immunosuppressive medication after one year.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes Mellitus
Keywords
Islet Transplantation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
3 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Islet Transplantation and Bone Marrow
Arm Type
Experimental
Arm Description
Administration of islets and infusion of CD34 enriched Bone Marrow cells in subjects with type 1 diabetes, impaired awareness of hypoglycemia and severe hypoglycemia.
Intervention Type
Biological
Intervention Name(s)
Islet Transplantation and Bone Marrow
Other Intervention Name(s)
Islet, type 1 DM, Bone marrow
Intervention Description
Islet transplantation and CD34 Bone Marrow infusion in subjects with type 1 diabetes.
Primary Outcome Measure Information:
Title
The Achievement of Persistent Islet Function Following Cessation of Immunosuppression.
Description
Immunosuppression was never discontinued. Patients elected to move to other trials to receive additional islet infusions. Since immunosuppression was never discontinued we were not able to evaluate the primary endpoint.
Time Frame
for the duration of islet graft function
Title
A Reduction or Absence of Rejection Episodes
Description
Number of rejection episodes after transplantation. Immunosuppression was never discontinued. Patients elected to move to other trials to receive additional islet infusions. Since immunosuppression was never discontinued we were not able to evaluate the primary endpoint.
Time Frame
for the duration of islet graft function
Secondary Outcome Measure Information:
Title
Number of Subjects With Basal C-peptide Greater Than 0.5 ng/ml
Description
Number of subjects with basal C-peptide greater than 0.5 ng/ml prior to weaning of immunosuppression;
Time Frame
for the duration of islet graft function
Title
Number of Subjects With Reduction of Severe Hypoglycemia and Improvement in Hypoglycemia Awareness
Description
Number of subjects with reduction of episodes of severe hypoglycemia and the presence of awareness of hypoglycemia
Time Frame
for the duration of islet graft function

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients between 18 and 65 years of age Patients with type 1 diabetes mellitus for more than 5 years duration One or more of the following: Hypoglycemia unawareness - judged by history of blood sugars <54 on glucometer without symptoms and/or hypoglycemic episodes requiring assistance from either family, glucagon administration or emergency services Poor diabetes control (HbA1c>8% or >2 visits/yr to hospital for treatment of ketoacidosis) despite intensive insulin therapy Progressive complications of type 1 diabetes mellitus Body Mass Index (BMI) ≤26 Exclusion Criteria: Untreated proliferative diabetic retinopathy; HbA1C > 12%; Insulin requirement > 1.0u/kg/d Stimulated or basal C-peptide > 0.3 ng/ml Creatinine clearance < 60 and/or serum creatinine consistently > 1.5mg/dl; Macroalbuminuria > 300mg albumin in 24 hours Presence of panel reactive antibodies > 20%; Previous/concurrent organ transplantation (except failed islet cell transplantation); Any medical condition requiring chronic use of steroids; Malignancy or previous malignancy (except non-melanomatous skin cancer); X-ray evidence of pulmonary infection; Active infections; Positive tuberculin test (unless proof of adequate treatment for latent tuberculosis can be provided) Active peptic ulcer disease, Gall stones and/or portal hypertension and/or hemangioma on liver ultrasound; Serological evidence of HIV, HBV (HBsAg+ and/or HBcAb+ and/or HBsAb+ without evidence of vaccination), HTLV-1 or HCV; Negative serology for Epstein Barr virus (EBV) or evidence of acute infection (IgM>IgG); Abnormal liver function test; Anemia (hemoglobin <12.0 g/dl); Hyperlipidemia (fasting total cholesterol >240mg/dl and/or fasting triglycerides >200mg/dl and/or fasting LDL cholesterol>140mg/dl); Body Mass Index above 26 and/or weight >80kg; Prostate specific antigen (PSA) > 4 ng/ml; Unstable cardiovascular status (including positive stress echocardiography if >age 35); Active alcohol or substance abuse; Sexually active females who are not: a) post-menopausal, b) surgically sterile, or c) not using an acceptable method of contraception (oral contraceptives, Norplant, Depo-Provera, and barrier devices are acceptable; condoms used alone are not acceptable); Positive pregnancy test or intent for future pregnancy, or male subject's intent to procreate. Any condition or any circumstances that makes it unsafe to undergo an islet cell transplant. History of previous transplant or previous bone marrow infusion. Persistent leucopenia (white blood cell count <3,000/mm3
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rodolfo Alejandro, MD
Organizational Affiliation
Diabetes Research Institute University of Miami
Official's Role
Principal Investigator
Facility Information:
Facility Name
Diabetes Research Institute
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Single arm few subjects.
Citations:
PubMed Identifier
19005394
Citation
Tharavanij T, Betancourt A, Messinger S, Cure P, Leitao CB, Baidal DA, Froud T, Ricordi C, Alejandro R. Improved long-term health-related quality of life after islet transplantation. Transplantation. 2008 Nov 15;86(9):1161-7. doi: 10.1097/TP.0b013e31818a7f45.
Results Reference
derived
Links:
URL
http://www.diabetesresearch.org
Description
Diabetes Research Institute web site

Learn more about this trial

Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus

We'll reach out to this number within 24 hrs